Shareholder Votes

Crocs, Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-06-09 meeting.

“The proposal regarding the advisory vote to approve the compensation of the Company’s named executive officers was approved based on the following votes”

Crocs, Inc. shareholders approved Ratify appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.

“The proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2026 was approved based on the following votes”

Crocs, Inc. shareholders approved Election of Class III directors at the 2026-06-09 meeting.

“The nominees for election as Class III directors to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified, were elected based on the following votes”

OFS Capital Corp shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“For Against Abstain 8,463,314 127,468 137,629”

OFS Capital Corp shareholders approved Election of two Class II directors at the 2026-06-10 meeting.

“Romita Shetty and Bilal Rashid were elected to serve as Class II Directors until the 2029 annual meeting of stockholders, or until their successors are elected and qualified”

QNB CORP. shareholders approved To ratify the appointment of Baker Tilly US, LLP as QNB’s independent registered public accounting firm for 2026 at the 2026-06-09 meeting.

“Proposal No. 3: To ratify the appointment of Baker Tilly US, LLP as QNB’s independent registered public accounting firm for 2026: Votes For Votes Against Abstain 3,210,074 9,332 17,344”

QNB CORP. shareholders approved To approve and adopt the 2026 Employee Stock Purchase Plan at the 2026-06-09 meeting.

“Proposal No. 2 : To approve and adopt the 2026 Employee Stock Purchase Plan: Votes Votes Broker For Against Abstain Non-Votes 2,630,365 35,230 24,958 546,197”

QNB CORP. shareholders approved Election of Class II Directors to serve a term of three years and until their successors are elected at the 2026-06-09 meeting.

“Proposal No. 1: Election of Class II Directors to serve a term of three years and until their successors are elected: Name Votes For Votes Withheld Broker Non-Votes Laurie A. Bergman 2,654,204 36,349 546,197 Randy S. Bimes 2,648,199 42,134 546,197 Kenneth F. Brown, Jr. 2,639,694 50,859 546,197 Randall E. Stauffer 2,639,847 50,706 546,197”

Orchid Island Capital, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on named executive officer compensation.

“Proposal 4—Advisory Vote on the Frequency of Future Advisory Votes on Named Executive Officer Compensation. The stockholders recommended, on an advisory basis, that future votes on named executive officer compensation be conducted every year 1 Year 2 Years 3 Years Abstain 64,123,663 933,219 2,096,040 1,531,799”

Orchid Island Capital, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers.

“Proposal 3—Advisory Vote on Named Executive Officer Compensation. This advisory vote was approved upon the following vote. For Against Abstain Broker Non-Votes 61,130,974 6,179,179 1,374,568 61,745,081”

Orchid Island Capital, Inc. shareholders approved Ratification of the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2026.

“Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm. This proposal was ratified upon the following vote. For Against Abstain Broker Non-Votes 121,803,409 6,850,503 1,775,890 N/A”

Orchid Island Capital, Inc. shareholders approved Election of six nominated directors to the Board.

“Proposal 1—Election of Directors. The following nominees were elected to our Board to serve until the next annual meeting of the Company’s stockholders or until his or her successor is elected and qualified: Robert E. Cauley, George H. Haas, IV, W Coleman Bitting, Frank P. Filipps, Paula Morabito and Ava L. Parker. Nominee for Director For Against Abstain Broker Non-Votes Robert E. Cauley 64,347,162 3,500,798 836,761 61,745,081 George H. Haas, IV 56,464,468 11,378,588 841,665 61,745,081 W Coleman Bitting 62,764,466 5,081,547 838,708 61,745,081 Frank P. Filipps 62,324,898 5,537,467 822,356 61,745,081 Paula Morabito 63,355,225 4,514,128 815,368 61,745,081 Ava L. Parker 61,525,593 6,346,437 812,691 61,745,081”

Strategy Inc shareholders approved To approve and adopt an amendment and restatement of the Certificate of Designations of the Company's Variable Rate Series A Perpetual Stretch Preferred Stock to provide for two scheduled dividend payment dates per month, instead of one, as disclosed in the proxy statement. at the 2026-06-08 meeting.

“To approve and adopt an amendment and restatement of the Certificate of Designations of the Company's Variable Rate Series A Perpetual Stretch Preferred Stock to provide for two scheduled dividend payment dates per month, instead of one, as disclosed in the proxy statement.”

Strategy Inc shareholders approved To ratify, pursuant to Section 204 of the General Corporation Law of the State of Delaware, the filing and effectiveness of the Certificate of Amendment to the Certificate of Designations of the Company's 8.00% Series A Perpetual Strike Preferred Stock filed with the Secretary of State of the State at the 2026-06-08 meeting.

“To ratify, pursuant to Section 204 of the General Corporation Law of the State of Delaware, the filing and effectiveness of the Certificate of Amendment to the Certificate of Designations of the Company's 8.00% Series A Perpetual Strike Preferred Stock filed with the Secretary of State of the State of Delaware on July 7, 2025, and the amendment to the liquidation preference of such stock effectuated thereby, as disclosed in the proxy statement.”

Strategy Inc shareholders approved To approve, on an advisory, non-binding basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. at the 2026-06-08 meeting.

“To approve, on an advisory, non-binding basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.”

Strategy Inc shareholders approved To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, as disclosed in the proxy statement. at the 2026-06-08 meeting.

“To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, as disclosed in the proxy statement.”

Strategy Inc shareholders approved To elect the following eight (8) directors for the next year at the 2026-06-08 meeting.

“To elect the following eight (8) directors for the next year: Class For Withheld Broker Non-votes Michael J. Saylor Common 321,909,589 16,834,278 73,095,003 Phong Q. Le Common 325,774,679 12,969,188 73,095,003 Brian P. Brooks Common 325,804,775 12,939,092 73,095,003 Jane A. Dietze Common 326,098,913 12,644,954 73,095,003 Stephen X. Graham Common 323,544,158 15,199,709 73,095,003 Jarrod M. Patten Common 324,237,991 14,505,876 73,095,003 Carl J. Rickertsen Common 306,098,976 32,644,891 73,095,003 Gregg J. Winiarski Common 325,727,519 13,016,348 73,095,003”

Aldeyra Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers (non-binding) at the 2026-06-09 meeting.

“Proposal 3: Advisory Vote on Executive Compensation. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 19,477,504 4,543,221 87,138 20,038,067”

Aldeyra Therapeutics, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“Proposal 2: Ratification of Appointment of BDO USA, P.C. The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining 43,693,772 321,501 130,657”

Aldeyra Therapeutics, Inc. shareholders approved Election of one director to serve as a Class III director at the 2026-06-09 meeting.

“Proposal 1: Election of Directors. The Company’s stockholders elected the following director to serve as a Class III director until the 2029 annual meeting of stockholders or until his successor is duly elected and qualified or until earlier death, resignation or removal. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Todd C. Brady, M.D., Ph.D. 23,026,101 1,081,762 20,038,067”

Metagenomi Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“Proposal 2 – The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstentions 18,483,295 51,847 581,065”

Metagenomi Therapeutics, Inc. shareholders approved Election of Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II Directors at the 2026-06-09 meeting.

“Proposal 1 - Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. were elected as Class II Directors to serve until the Company’s 2029 annual meeting of stockholders, and until their respective successor shall have been duly elected and qualified, or until their earlier death, resignation or removal, based on the following votes: Class II Director Nominee For Withheld Broker Non-Votes Juergen Eckhardt, M.D., M.B.A. 7,296,718 1,436,882 10,382,607 Eric Bjerkholt, M.B.A. 8,251,289 482,311 10,382,607”

P3 Health Partners Inc. shareholders approved Approval, in accordance with Nasdaq Listing Rule 5635(d), the issuance of up to 3,341,130 shares of Class A common stock upon the exercise of outstanding Class A common stock warrants held by VBC Growth SPV 5, LLC. at the 2026-06-09 meeting.

“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”

P3 Health Partners Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. at the 2026-06-09 meeting.

“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”

P3 Health Partners Inc. shareholders approved Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-09 meeting.

“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”

P3 Health Partners Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2029, and until their respective successors have been duly elected and qualified. at the 2026-06-09 meeting.

“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”

Vitesse Energy, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm.

“Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm . Deloitte & Touche LLP was ratified as the Company’s independent registered public accounting firm for 2026. The voting results were as follows: VOTES FOR VOTES AGAINST VOTES ABSTAINED 29,213,741 821,700 167,487”

Vitesse Energy, Inc. shareholders approved Election of Directors.

“Proposal No. 1 - Election of Directors . Each of the directors that were up for election was elected for a term of one year. Votes regarding the election of these directors were as follows: NOMINEE VOTES FOR VOTES AGAINST VOTES ABSTAINED BROKER NON-VOTES Linda L. Adamany 21,576,304 1,448,566 148,878 7,029,180 Jamie Benard 21,787,202 1,218,347 168,199 7,029,180 Brian P. Friedman 21,792,301 1,230,719 150,728 7,029,180 Daniel J. O’Leary 20,633,790 2,394,034 145,924 7,029,180 Cathleen M. Osborn 21,631,399 1,388,453 153,896 7,029,180 Gary D. Reaves 22,032,901 985,413 155,434 7,029,180 Randy I. Stein 21,676,465 1,341,730 155,553 7,029,180 Joseph S. Steinberg 19,955,842 3,062,853 155,053 7,029,180”

Bluejay Diagnostics, Inc. shareholders approved Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026. at the 2026-06-09 meeting.

“Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results for the proposal were as follows: Votes For Votes Against Abstentions 389,052 21,067 3,973”

Bluejay Diagnostics, Inc. shareholders approved Approve and adopt an amendment to the Company’s stock plan to increase the number of shares available for issuance thereunder from 61 shares to 600,061 shares. at the 2026-06-09 meeting.

“Proposal 3. Approve and adopt an amendment to the Company’s stock plan to increase the number of shares available for issuance thereunder - The Company’s stockholders approved and adopted the Plan Amendment to increase the number of shares of common stock issuable under the Stock Plan by 600,000 (from 61 shares to 600,061 shares). The voting results for the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 135,750 94,058 1,160 183,124”

Bluejay Diagnostics, Inc. shareholders approved Election of Directors - Re-election of Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth and Fred Zeidman to serve until the 2027 annual meeting. at the 2026-06-09 meeting.

“Proposal 1. Election of Directors - The Company’s stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth and Fred Zeidman to serve as directors until the Company’s 2027 annual meeting of stockholders, or until their successors are duly elected and qualified. The voting results for the proposal were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Donald Chase 207,410 23,558 183,124 Neil Dey 207,842 23,126 183,124 Svetlana Dey 207,327 23,641 183,124 Douglas Wurth 207,337 23,631 183,124 Fred Zeidman 207,334 23,634 183,124”

Axsome Therapeutics, Inc. shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers at the 2026-06-05 meeting.

“Proposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers. The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 37,818,384 777,937 366,155 4,815,060”

Axsome Therapeutics, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-05 meeting.

“Proposal 2: Ratification of Appointment of Deloitte & Touche LLP. The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 43,278,147 14,407 484,982 0”

Axsome Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-05 meeting.

“Proposal 1: Election of Class II Directors. The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the Class II directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Mark Saad 28,675,654 10,286,822 4,815,060 Susan Mahony, Ph.D., MBA 29,892,131 9,070,345 4,815,060”

Avalon GloboCare Corp. shareholders approved Approval to give the Board authority to effect a reverse stock split of the Company's issued common stock at a ratio between 1-for-2 and 1-for-25, with the exact ratio to be selected by the Board, to be effected before June 9, 2027 (the 'Reverse Stock Split Proposal') at the 2026-06-09 meeting.

“the stockholders approved the Reverse Stock Split Proposal. The result of the votes to approve the Reverse Stock Split Proposal was as follows: For Against Abstain Broker Non-Votes 3,605,584 741,154 17,952 0”

Avalon GloboCare Corp. shareholders approved Approval, for the purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of Series A-1 Warrants, Series A-2 Warrants, Placement Agent Warrants and shares issuable upon exercise thereof in connection with the February 2026 private placement (the 'February 2026 Warrant Issuance Propos at the 2026-06-09 meeting.

“the stockholders approved the February 2026 Warrant Issuance Proposal. The result of the votes to approve the February 2026 Warrant Issuance Proposal was as follows: For Against Abstain Broker Non-Votes 925,882 570,691 4,417 2,863,700”

Avalon GloboCare Corp. shareholders approved Advisory approval of the 2025 compensation of our named executive officer (the 'Say-on-Pay Proposal') at the 2026-06-09 meeting.

“the stockholders approved the Say-on-Pay Proposal . The result of the votes to approve the Say-on-Pay Proposal was as follows: For Against Abstain Broker Non-Votes 1,414,027 32,635 54,328 2,863,700”

Avalon GloboCare Corp. shareholders approved Approval of the Avalon GloboCare Corp. 2026 Stock Incentive Plan (the '2026 Plan Proposal') at the 2026-06-09 meeting.

“the stockholders approved the 2026 Plan Proposal. The result of the votes to approve the 2026 Plan Proposal was as follows: For Against Abstain Broker Non-Votes 880,827 618,585 1,578 2,863,700”

Avalon GloboCare Corp. shareholders approved Ratification of the appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“appointment of M&K as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non-Votes 4,250,597 110,736 3,357 0”

Avalon GloboCare Corp. shareholders approved Election of four (4) members of the Board to serve for a one-year term to expire at the 2027 annual meeting at the 2026-06-09 meeting.

“All of the four (4) nominees for director were elected to serve until the next annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”

BIMINI CAPITAL MANAGEMENT, INC. shareholders approved Advisory Vote on 2025 Executive Compensation at the 2026-06-09 meeting.

“Advisory Vote on 2025 Executive Compensation.”

BIMINI CAPITAL MANAGEMENT, INC. shareholders approved Approval of First Amendment to the Company's Rights Agreement at the 2026-06-09 meeting.

“Approval of First Amendment to the Company's Rights Agreement.”

BIMINI CAPITAL MANAGEMENT, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

“Ratification of Appointment of Independent Registered Public Accounting Firm.”

BIMINI CAPITAL MANAGEMENT, INC. shareholders approved Election of one Class II Director at the 2026-06-09 meeting.

“Election of one Class II Director.”

TALOS ENERGY INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.

“4. The Board’s proposal seeking the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved. The voting results were as follows: VOTES FOR VOTES AGAINST VOTES ABSTAINED 149,839,839.13 558,749.00 337,717.00”

TALOS ENERGY INC. shareholders approved Approval of the A&R LTIP.

“3. The Company’s stockholders approved the A&R LTIP. The voting results were as follows: VOTES FOR VOTES AGAINST VOTES ABSTAINED BROKER NON-VOTES 140,631,798.31 3,153,680.00 511,686.00 6,439,140.82”

TALOS ENERGY INC. shareholders approved Approval, on a non-binding advisory basis, of the Company's named executive officers' compensation for the fiscal year ended December 31, 2025 at the 2025-12-31 meeting.

“2. The Board’s proposal seeking approval, on a non-binding advisory basis, of the Company’s NEOs’ compensation for the fiscal year ended December 31, 2025 was approved. The voting results were as follows: VOTES FOR VOTES AGAINST VOTES ABSTAINED BROKER NON-VOTES 134,898,126.31 6,416,219.00 2,982,819.00 6,439,140.82”

TALOS ENERGY INC. shareholders approved Election of Director Nominees.

“1. The director nominees that were up for election at the Annual Meeting were each elected for a one-year term expiring at the 2027 Annual Meeting, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. Votes regarding the election of the following director nominees were as follows: NOMINEE VOTES FOR VOTES AGAINST VOTES ABSTAINED BROKER NON-VOTES Mr. Neal P. Goldman 120,820,103.31 23,155,957.00 321,104.00 6,439,140.82 Mr. Paul R. Goodfellow 141,040,000.31 2,927,824.00 329,340.00 6,439,140.82 Mr. John “Brad” Juneau 137,378,342.31 6,597,332.00 321,490.00 6,439,140.82 Mr. Richard M. Sherrill 141,001,112.31 2,965,646.00 330,406.00 6,439,140.82 Mr. Charles M. Sledge 134,485,887.31 9,481,045.00 330,232.00 6,439,140.82 Ms. Shandell M. Szabo 143,101,630.31 857,047.00 338,487.00 6,439,140.82”

Ulta Beauty, Inc. shareholders approved Approve the Ulta Beauty, Inc. 2026 Incentive Award Plan. at the 2026-06-09 meeting.

“The stockholders approved the 2026 Plan. The results of the vote were as follows: For Against Abstain Broker Non-Votes Votes Percentage (1) Votes Percentage (1) Votes Percentage (1) Votes Percentage (2) 31,757,224 89.92% 3,514,995 9.95% 43,702 0.12% 2,765,202 N/A”

Ulta Beauty, Inc. shareholders approved Advisory vote to approve the company's executive compensation. at the 2026-06-09 meeting.

“The stockholders approved the Company's executive compensation. The results of the advisory vote were as follows: For Against Abstain Broker Non-Votes Votes Percentage (1) Votes Percentage (1) Votes Percentage (1) Votes Percentage (2) 27,487,649 77.83% 7,777,149 22.02% 51,123 0.14% 2,765,202 N/A”